Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Sr. VP & CFO | September 02, 2016 | September 07, 2016 |
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | May 30, 2024 | June 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date September 02, 2016 · Filed September 07, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 83,586 |
Reported balance
After 2016-09-02 transaction · row 1
1 source rowRow 1 · 2016-09-02 · Exercise / conversion · Acquired 10,000 · Balance 83,586 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2021-08-05 | Direct | 25,000 |
Reported balance
After 2016-09-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-02 · Exercise / conversion · Disposed 10,000 · Balance 25,000 F1: As of August 5, 2015, the option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: As of August 5, 2015, the option is fully vested.
Corbus Pharmaceuticals Holdings, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 4,350 |
Reported balance
After 2024-05-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 2,783 · Balance 4,350 F1: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2: This amount includes 2,783 unvested RSUs that were granted on May 30, 2024 and will vest 100% on the one-year anniversary from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
F2: This amount includes 2,783 unvested RSUs that were granted on May 30, 2024 and will vest 100% on the one-year anniversary from the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Provention Bio, Inc.
Report date April 27, 2023 · Filed April 27, 2023
Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Avery W. Catlin Revocable Trust | 0 |
Reported balance
After 2023-04-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-04-27 · Other · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $25.00 in cash (the "Offer Price") without interest and subject to applicable withholding of taxes. |
| Common StockSEC Table I · non-derivative | IndirectBy the Avery Catlin Charitable Giving Fund | 0 |
Reported balance
After 2023-04-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-04-27 · Other · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $25.00 in cash (the "Offer Price") without interest and subject to applicable withholding of taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.88 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-27 · Disposition to issuer · Disposed 128,981 · Balance 0 F2: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.54 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-04-27 · Disposition to issuer · Disposed 24,000 · Balance 0 F2: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.62 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-04-27 · Disposition to issuer · Disposed 22,200 · Balance 0 F2: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.80 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-04-27 · Disposition to issuer · Disposed 23,000 · Balance 0 F2: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.52 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-04-27 · Disposition to issuer · Disposed 33,000 · Balance 0 F2: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $25.00 in cash (the "Offer Price") without interest and subject to applicable withholding of taxes.
F2: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full.
F3: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 30, 2024 Filed Jun 3, 2024 16:31 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068035 · ownership.xml · nonDerivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,350 F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 2,783 unvested RSUs that were granted on May 30, 2024 and will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 16, 2024 Filed May 20, 2024 16:55 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 2,783 | $0.00 Strike: $45.92 | $0.00 |
DisclosureSEC source: 0001209191-24-005672 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 Underlying: Common Stock · 2,783 shares Expires 2034-05-16 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 18, 2023 Filed May 22, 2023 16:17 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001209191-23-031441 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2033-05-18 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest 100% on the one year anniversay from the date of grant. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:02 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 33,000 | Not disclosed Strike: $4.52 | Not disclosed |
DisclosureSEC source: 0001493152-23-013910 · ownership.xml · derivative · entry 7 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,000 shares Expires not disclosed F2 · price: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:02 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 23,000 | Not disclosed Strike: $6.80 | Not disclosed |
DisclosureSEC source: 0001493152-23-013910 · ownership.xml · derivative · entry 6 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,000 shares Expires not disclosed F2 · price: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:02 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 22,200 | Not disclosed Strike: $12.62 | Not disclosed |
DisclosureSEC source: 0001493152-23-013910 · ownership.xml · derivative · entry 5 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,200 shares Expires not disclosed F2 · price: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:02 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 24,000 | Not disclosed Strike: $12.54 | Not disclosed |
DisclosureSEC source: 0001493152-23-013910 · ownership.xml · derivative · entry 4 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · price: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:02 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 128,981 | Not disclosed Strike: $3.88 | Not disclosed |
DisclosureSEC source: 0001493152-23-013910 · ownership.xml · derivative · entry 3 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128,981 shares Expires not disclosed F2 · price: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F3 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:02 UTC | Provention Bio, Inc. PRVB · Entity 12101 | OtherCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-013910 · ownership.xml · nonDerivative · entry 2 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Avery Catlin Charitable Giving Fund Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $25.00 in cash (the "Offer Price") without interest and subject to applicable withholding of taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $25.00 in cash (the "Offer Price") without interest and subject to applicable withholding of taxes. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:02 UTC | Provention Bio, Inc. PRVB · Entity 12101 | OtherCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-013910 · ownership.xml · nonDerivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Avery W. Catlin Revocable Trust Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $25.00 in cash (the "Offer Price") without interest and subject to applicable withholding of taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $25.00 in cash (the "Offer Price") without interest and subject to applicable withholding of taxes. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 17:24 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-012387 · ownership.xml · nonDerivative · entry 2 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Avery Catlin Charitable Giving Fund Disclosed balance after: 10,000 F1 · kind: This transaction involved a bona fide gift of securities by the reporting person to the Avery Catlin Charitable Giving Fund. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 17:24 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-012387 · ownership.xml · nonDerivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · kind: This transaction involved a bona fide gift of securities by the reporting person to the Avery Catlin Charitable Giving Fund. Read SEC document |
| May 18, 2022 Filed May 19, 2022 14:23 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 79,600 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-22-030437 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,600 Underlying: Common Stock · 79,600 shares Expires 2032-05-18 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 17, 2022 Filed May 18, 2022 18:04 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001493152-22-014366 · ownership.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock, par value $0.0001 · 33,000 shares Expires 2032-05-17 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 17, 2023. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 16:40 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041455 · doc4.xml · derivative · entry 2 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 16:40 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041455 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:48 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001493152-21-011589 · ownership.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock, par value $0.0001 · 23,000 shares Expires 2031-05-12 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 12, 2022. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 18:01 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 22,200 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001493152-20-013477 · ownership.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,200 Underlying: Common Stock, par value $0.0001 · 22,200 shares Expires 2030-07-15 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: 22,200 option shares vest on July 15, 2021. Read SEC document |
| May 20, 2020 Filed May 22, 2020 15:00 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 40,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-20-031659 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 24,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001493152-19-009698 · ownership.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock, par value $0.0001 · 24,000 shares Expires 2029-06-24 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The option fully vests on May 28, 2020. Read SEC document |
| May 22, 2019 Filed Jun 28, 2019 16:02 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 33,300 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001209191-19-039459 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,300 Underlying: Common Stock · 33,300 shares Expires 2029-05-22 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| December 26, 2018 Filed Dec 27, 2018 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 5,000 | $1.85 | $9,250.00 |
DisclosureSEC source: 0001493152-18-018016 · ownership.xml · nonDerivative · entry 2 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Avery W. Catlin Revocable Trust Disclosed balance after: 20,000 Read SEC document |
| December 24, 2018 Filed Dec 27, 2018 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 5,000 | $1.90 | $9,500.00 |
DisclosureSEC source: 0001493152-18-018016 · ownership.xml · nonDerivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Avery W. Catlin Revocable Trust Disclosed balance after: 15,000 Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 07:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 10,000 | $3.15 | $31,500.00 |
DisclosureSEC source: 0001493152-18-015651 · ownership.xml · nonDerivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Avery W. Catlin Revocable Trust Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.09 to $3.17, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 05, 2018 Filed Sep 5, 2018 21:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 128,981 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001493152-18-012925 · ownership.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,981 Underlying: Common Stock, par value $0.0001 · 128,981 shares Expires 2028-09-05 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The option vests in eight equal semi-annual installments commencing on March 5, 2019 and will become fully vested on September 5, 2022. Read SEC document |
| May 24, 2018 Filed May 29, 2018 16:07 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 34,000 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0001209191-18-033766 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2028-05-24 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:39 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 30,500 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0001209191-17-035856 · doc4.xml · derivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2027-05-25 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 11, 2017 Filed May 12, 2017 10:46 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 5,000 | $6.15 | $30,740.50 |
DisclosureSEC source: 0001209191-17-031737 · doc4.xml · nonDerivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 14:40 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 2,000 | $7.55 | $15,100.00 |
DisclosureSEC source: 0001209191-16-151670 · doc4.xml · nonDerivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 16:59 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001179110-16-029382 · edgar.xml · derivative · entry 2 CATLIN AVERY W · CIK 0001255348 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 10,000 shares Expires 2021-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: As of August 5, 2015, the option is fully vested. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 16:59 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | Exercise / conversionCommon Stock, par value $0.001 per share | 10,000 | $2.80 | $28,000.00 |
DisclosureSEC source: 0001179110-16-029382 · edgar.xml · nonDerivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.